Skip to content

Immunome IMNM Cash Flow Statement

Q1 '26Q4 '25Q3 '25Q2 '25Q1 '25
-$53.84M-29.3%-$69.9M+12.9%-$57.46M-22.0%-$43.4M-20.1%-$41.64M+67.8%
$603K-1.3%$629K+39.8%$589K+43.3%$637K+16.0%$611K+289%
$7.95M+39.5%$7.89M+44.3%$6.75M+37.9%$5.35M+65.7%$5.7M+164%
-$58.64M-10.5%-$47.95M-14.0%-$40.51M-18.6%-$49.4M-111%-$53.06M-375%
$3M-18.1%$4M+255%$1.12M-27.5%$905K-61.4%$3.67M+69.4%
-$12.02M-336%$0$123.88M-$64.17M+21.4%$5.09M+114%
-$135K-100%$432.8M+2,055%$45.39M+14,782%$0-100%$162.23M-26.1%
-$70.79M-162%$380.84M$128.76M$114.26M-33.2%
-$61.64M-8.7%-$51.95M-20.3%-$41.63M-16.6%-$50.31M-95.4%-$56.72M-325%

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

How much cash does Immunome generate?
Immunome (IMNM) generated -$196.5M in operating cash flow over the trailing twelve months.
What is Immunome's free cash flow?
After $9.0M of capital expenditures, Immunome's free cash flow was -$205.5M over the trailing twelve months, down 27.4% year over year.
Where does Immunome's cash flow data come from?
Every line is extracted from Immunome's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.